Expression of CD68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis
| Autor: | Per-Ola Andersson, Margret Sigurdardottir, Sverker Hasselblom, Börje Ridell, Ulrika Hansson, Herman Nilsson-Ehle |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Pathology medicine.medical_specialty Population Antigens Differentiation Myelomonocytic Cell Count Disease-Free Survival Pathology and Forensic Medicine Immunophenotyping Antigens CD Biomarkers Tumor Humans Medicine education Survival rate Aged Neoplasm Staging Sweden education.field_of_study business.industry CD68 Macrophages Germinal center Cancer General Medicine Middle Aged Germinal Center Prognosis medicine.disease Combined Modality Therapy Lymphoma Survival Rate Ki-67 Antigen Female Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma |
| Zdroj: | Pathology International. 58:529-532 |
| ISSN: | 1440-1827 1320-5463 |
| DOI: | 10.1111/j.1440-1827.2008.02268.x |
| Popis: | Tumor-associated macrophages (TAM) have been ascribed both pro- and anti-tumor properties, but the majority of clinical cancer studies have shown that the presence of a high number of TAM is related to poor prognosis, suggesting that TAM predominantly exert pro-tumoral activity. The prognostic role of TAM in patients with diffuse large B-cell lymphoma (DLBCL), however, is so far unknown. Therefore, TAM were immunohistochemically stained with a CD68 antibody in a retrospective, population-based study including 176 DLBCL patients treated with curative intent. With the exception that patients >60 years of age had a larger number of CD68+ cells (1143 vs 1018 cells/mm2; P = 0.05), no significant differences were found between the number of CD68+ cells and other clinical factors. Similarly, germinal center B-cell (GCB)/non-GCB immunophenotype or low/high Ki-67 percentage were not associated with CD68 expression. Finally, no significant correlation was found between the number of CD68+ cells and progression-free survival (P = 0.34) or overall survival (P = 0.94). These data indicate that the pro-tumor effect of TAM has limited clinical relevance in DLBCL patients, which could imply that therapeutic strategies aimed at enhancing their anti-tumor activity are of continuous clinical interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|